Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
ISS03 - Industry Supported Symposium: Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Receptor as a Target for Monotherapy and in Combination – Merck-Pfizer Alliance
- Type: Industry Supported Symposium
- Track:
- Presentations: 6
- Moderators:S. Popat
- Coordinates: 12/04/2016, 15:30 - 17:00, Hall C2
-
+
ISS03.05 - Anti-PD-L1 Agents: Opportunities for Differentiation
16:30 - 16:45 | Author(s): H. Borghaei
- Abstract
No abstract available for this presentation
-
+
OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
- Type: Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 8
- Moderators:L. Crinò
- Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
-
+
OA03.01 - First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 (Abstract under Embargo until December 5, 7:00 CET)
11:00 - 11:10 | Author(s): S.N. Gettinger
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA03.05 - Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (Abstract under Embargo until December 5, 7:00 CET)
11:45 - 11:55 | Author(s): S. Peters
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA07 - ALK-ROS1 in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:N. Singh
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 1-2
-
+
MA07.02 - Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
11:06 - 11:12 | Author(s): D..R. Camidge
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA10 - EGFR Mutations
- Type: Oral Session
- Track: Biology/Pathology
- Presentations: 8
- Moderators:J. Spicer
- Coordinates: 12/06/2016, 11:00 - 12:30, Strauss 1
-
+
OA10.04 - Discussant for OA10.01, OA10.02, OA10.03
11:30 - 11:45 | Author(s): H. Borghaei
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA09 - Immunotherapy Combinations
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:M. Sebastian
- Coordinates: 12/06/2016, 14:20 - 15:50, Strauss 2
-
+
MA09.02 - Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G
14:26 - 14:32 | Author(s): C. Langer
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.03a - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 72
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-018 - A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC
14:30 - 14:30 | Author(s): J.L. Godwin
- Abstract
Loading... -
+
P2.03a-044 - Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second-Line Therapy
14:30 - 14:30 | Author(s): H. Borghaei
- Abstract
Loading...
-
+
P2.03b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 98
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-048 - Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer
14:30 - 14:30 | Author(s): A.K. Ganti
- Abstract
Loading...
-
+
P2.06 - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
- Presentations: 47
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.06-014 - Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy
14:30 - 14:30 | Author(s): J. Nemunaitis
- Abstract
Loading...
-
+
MA16 - Novel Strategies in Targeted Therapy
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:G. Purkalne
- Coordinates: 12/07/2016, 14:20 - 15:50, Strauss 2
-
+
MA16.10 - Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates
15:20 - 15:26 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.